November 19, 2015 7:29am

ATHX reported that multipotent adult progenitor cells, used in its MultiStem cell therapy, are effective in improving the health of animals after acute rodent spinal cord injury 


 

ATHX announced that multipotent adult progenitor cells, used in MultiStem cell therapy currently in clinical development, are effective in improving the health of animals after acute rodent spinal cord injury. Intravenous administration of MAPC one day after injury prevented loss of spinal cord tissue resulting in significant improvement of walking function and urinary control.

 

The Bottom Line: In the study, a single dose of MAPC was administered to rodents one day following severe spinal cord injury. Injured animals that received treatment demonstrated significantly improved voluntary control of bladder function, walking ability and preservation of at-risk nervous tissue. Further, the study defines a key mechanism of action of MAPC treatment, which occurs through the modulation of neuro-inflammation, including a significant reduction of inflammatory cell accumulation within the injury.

 

ATHX closed at $1.01 which was DOWN -$0.02 and has left investors hanging – TOO often! How far back do investors have to go back for the real high – 10/12/07 for $8.00?